retatrutide glp-1 medication Promises Big Weight Loss, but Safety Remains a Question new glp 1 drug retatrutide

The cumulative literature represents an active expansion-era research stream where new findings appear regularly across the international peer-reviewed publication record

The SOUL study of oral semaglutide confirms cardiovascular benefits in those with type 2 diabetes and established atherosclerotic cardiovascular disease at doses up to 14 mg (McGuire et al, 2025

PKA, protein Kinase A

importantly, peer-reviewed 2 work characterizes LR3s structure/processing and confirms it remains an active IGF-1R ligand

Advantages Reduction of pigmentation intensity Brightens areas of hyperpigmentation and evens out skin tone

Liu J., et al